| scholarly article | Q13442814 |
| P50 | author | Shaomeng Wang | Q44006873 |
| Haiying Sun | Q88797882 | ||
| P2093 | author name string | Liu Liu | |
| Chao-Yie Yang | |||
| Jianfeng Lu | |||
| P2860 | cites work | IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer | Q24292870 |
| Distinct BIR domains of cIAP1 mediate binding to and ubiquitination of tumor necrosis factor receptor-associated factor 2 and second mitochondrial activator of caspases | Q24294565 | ||
| IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis | Q24300707 | ||
| IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis | Q24300734 | ||
| Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis | Q24609324 | ||
| Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain | Q27629143 | ||
| Structural basis of IAP recognition by Smac/DIABLO | Q27629148 | ||
| Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs | Q27643305 | ||
| Structure-Based Design, Synthesis, Evaluation, and Crystallographic Studies of Conformationally Constrained Smac Mimetics as Inhibitors of the X-linked Inhibitor of Apoptosis Protein (XIAP) † | Q27652682 | ||
| Orally bioavailable antagonists of inhibitor of apoptosis proteins based on an azabicyclooctane scaffold | Q27653852 | ||
| Antagonism of c-IAP and XIAP proteins is required for efficient induction of cell death by small-molecule IAP antagonists | Q27655724 | ||
| Discovery of a Potent Small-Molecule Antagonist of Inhibitor of Apoptosis (IAP) Proteins and Clinical Candidate for the Treatment of Cancer (GDC-0152) | Q27678027 | ||
| Design and synthesis of potent inhibitor of apoptosis (IAP) proteins antagonists bearing an octahydropyrrolo[1,2-a]pyrazine scaffold as a novel proline mimetic | Q27683730 | ||
| Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition | Q28115131 | ||
| Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins | Q28117928 | ||
| Development and validation of a genetic algorithm for flexible docking | Q28236574 | ||
| IAP family proteins--suppressors of apoptosis | Q28297514 | ||
| Improved protein-ligand docking using GOLD | Q29616787 | ||
| IAP proteins: blocking the road to death's door | Q29619844 | ||
| Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias | Q31379722 | ||
| Nonpeptidic and potent small-molecule inhibitors of cIAP-1/2 and XIAP proteins | Q34116053 | ||
| XIAP: apoptotic brake and promising therapeutic target. | Q34303728 | ||
| A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death | Q34346499 | ||
| Caspases, IAPs and Smac/DIABLO: mechanisms from structural biology | Q35874476 | ||
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment | Q36460712 | ||
| Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP | Q36909606 | ||
| Inhibitor of apoptosis proteins as targets for anticancer therapy | Q36950485 | ||
| The inhibitor of apoptosis proteins as therapeutic targets in cancer | Q36975583 | ||
| Design, synthesis, and evaluation of tricyclic, conformationally constrained small-molecule mimetics of second mitochondria-derived activator of caspases | Q37143013 | ||
| Design of small-molecule peptidic and nonpeptidic Smac mimetics | Q37176751 | ||
| Potent, orally bioavailable diazabicyclic small-molecule mimetics of second mitochondria-derived activator of caspases | Q37185121 | ||
| A potent bivalent Smac mimetic (SM-1200) achieving rapid, complete, and durable tumor regression in mice | Q37249659 | ||
| IAP-targeted therapies for cancer | Q37302745 | ||
| SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. | Q37445045 | ||
| Design, synthesis, and evaluation of potent, nonpeptidic mimetics of second mitochondria-derived activator of caspases | Q37481457 | ||
| IAP antagonists: promising candidates for cancer therapy | Q37680131 | ||
| Targeting IAP proteins for therapeutic intervention in cancer | Q37980321 | ||
| Requirement of Both the Second and Third BIR Domains for the Relief of X-linked Inhibitor of Apoptosis Protein (XIAP)-mediated Caspase Inhibition by Smac | Q39389950 | ||
| Discovery of aminopiperidine-based Smac mimetics as IAP antagonists | Q39408947 | ||
| A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling | Q40033734 | ||
| Design, synthesis, and evaluation of a potent, cell-permeable, conformationally constrained second mitochondria derived activator of caspase (Smac) mimetic. | Q40192019 | ||
| Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer | Q40524353 | ||
| Structure-based design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein/caspase-9 interaction site. | Q40528633 | ||
| IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes. | Q52009124 | ||
| Expression of the IAP protein family is dysregulated in pancreatic cancer cells and is important for resistance to chemotherapy | Q79801646 | ||
| Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis | Q79857928 | ||
| Design of Small-Molecule Smac Mimetics as IAP Antagonists | Q82436664 | ||
| Structure-based design of potent, conformationally constrained Smac mimetics | Q95801450 | ||
| P433 | issue | 4 | |
| P921 | main subject | cell death | Q2383867 |
| P304 | page(s) | 994-1002 | |
| P577 | publication date | 2014-02-12 | |
| P1433 | published in | ACS Chemical Biology | Q165583 |
| P1476 | title | Potent and selective small-molecule inhibitors of cIAP1/2 proteins reveal that the binding of Smac mimetics to XIAP BIR3 is not required for their effective induction of cell death in tumor cells | |
| P478 | volume | 9 |
| Q40555960 | Absence of RIPK3 predicts necroptosis resistance in malignant melanoma |
| Q35774947 | Avian pathogenic Escherichia coli (APEC) infection alters bone marrow transcriptome in chickens |
| Q33918811 | Centrosomal protein 55 activates NF-κB signalling and promotes pancreatic cancer cells aggressiveness |
| Q60302272 | DEBIO 1143, an IAP inhibitor, reverses carboplatin resistance in ovarian cancer cells and triggers apoptotic or necroptotic cell death |
| Q89235427 | Design of Potent pan-IAP and Lys-Covalent XIAP Selective Inhibitors Using a Thermodynamics Driven Approach |
| Q89777233 | IAPs protect host target tissues from graft-versus-host disease in mice |
| Q35780628 | Lipid-conjugated Smac analogues |
| Q40648639 | Molecular Pathways: The Balance between Cancer and the Immune System Challenges the Therapeutic Specificity of Targeting Nuclear Factor-κB Signaling for Cancer Treatment |
| Q34263719 | Small-molecule inhibitors of protein-protein interactions: progressing toward the reality |
| Q102075600 | Snapshots and ensembles of BTK and cIAP1 protein degrader ternary complexes |
Search more.